Skip to main content
. 2020 Nov 30;11(3):e2. doi: 10.5037/jomr.2020.11302

Table 2.

Histomorphometric outcomes after maxillary sinus floor augmentation with autogenous bone graft compared with alternate grafting materials

Study Year of
publication 		Number of patients Materials and methods Outcome measures
Maxillary sinus floor augmentation RBH
(mm) 		Type of grafting material Length of
observation period
(months) 		Number of biopsies Bone-to-implant
contact
(%) 		Bone regeneration
TBV, BAF or NFB Non-mineralized tissue Residual graft
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Tadjoedin et al. [30] 2000 10 10 < 3 50% Biogran®; 50% autogenous 4 - 16 36 NR 4 month 5 month 6 month 16 month NR NR
28.5 (1.4) 34.5 (1.6) 38.1 (5.7) 44.5
10 Autogenous 36 40.9 (3.3) 42.2 (4.5) 43.7 (2.4) 45.1
Hallman et al. [31] 2002 21 11 < 5 20% Bio-Oss®; 80% autogenous 6.5 8 54.3 (33.1) 39.9 (8) NR 12.3 (8.5)
11 Autogenous 8 34.6 (9.5) 37.7 (31.3) NR
Zerbo et al. [32] 2004 9 9 4 - 8 Cerasorb® 6 32 NR 17 (5) NR NR
5 Autogenous 18 41 (10)a
Barone et al. [33] 2005 18 18 < 3 OsteoBiol® 5 NR NR 67 (14.9) NR NR
18 Autogenous 70 (19.9)
Szabó et al. [34] 2005 20 20 < 5 Cerasorb® 6 40 NR 36.5 (6.9) NR NR
20 Autogenous 40 38.3 (7.4)
Bettega et al. [35] 2009 18 9 3 Autogenous mixed with PRP 6 9 NR 43.2 NR NR
9 3.5 Autogenous 9 50
Johansson et al. [36] 2013 24 10 4.3 Bloodclot 7 10 93.5 (3.3) NR NR NR
10 3.5 Bloodclot and membrane 9 92 (4.1)
10 4.3 Autogenous 10 93.5 (3.3)
Khairy et al. [37] 2013 15 10 < 5 Autogenous mixed with PRP 4 - 6 NR NR 4 month 6 month NR NR
27.3 (6.3) 28 (4.1)
5 Autogenous 6 NR 39.5 (7.4)b
Schmitt et al. [38] 2013 30 45 2.3 BoneCeramic® 5 14 NR 30.3 (2.2) 55.2 (5.6) 15.2 (2.1)
2.5 Bio-Oss® 15 24.9 (5.7) 53.7 (8.1) 21.4 (4.8)
NR
2.6 Puros® 12 35.4 (2.8) 64.6 (2.8)
2.2 Autogenous 12 42.7 (2.1)c 57.3 (2.1)
Tosta et al. [39] 2013 30 15 4.1 BoneCeramic® 9 NR NR Intermediate Apical Intermediate Apical NR
33.7 (8.1) 26.7 (3.9) 33.4 (8) 39.6 (11.1)
15 Autogenous 41 (4.6)d 38.6 (7.5)e 59.2 (4.7)f 60.6 (7.2)g
Xavier et al. [40] 2015 15 15 ≤ 3 Fresh frozen bone 6 15 NR 8.3 (3) 56.8 (7.3) 34.9 (6.4)
15 Autogenous 15 8.3 (3.4) 55.6 (14.5) 36.1 (12.8)
Danesh-Sani et al. [41] 2016 10 10 < 5 BoneCeramic® 6 - 8 10 NR 28.2 (8.4) 38.9 (14.9) 32.9 (8.1)
10 Autogneous 10 36.8 (11.5)h 58.4 (10)i 4.8 (2.4)j
Pereira et al. [42] 2017 30 10 < 5 Biogran® 6 NR NR Intermediate Apical Intermediate Apical NR
40.7 (14) 45.6 (13.5) 56.6 (15.3) 47.9 (12.1)
10 50% Biogran®; 50% autogenous 33.2 (13.3) 45.8 (13.9) 62.5 (14.7) 48.8 (17.7)
10 Autogenous 35.3 (14.7) 39.9 (15.8) 61.2 (15.7) 57.8 (16.2)
Pereira et al. [43] 2017 22 12 < 5 chronOS® 6 NR NR Intermediate Apical Intermediate Apical NR
47.6 (9.9) 44.8 (22.1) 52.3 (9.9) 55.1 (22.1)
12 50% chronOS®; 50% autogenous 32.5 (13.7) 32.8 (16) 60.1 (13.9) 55.5 (9.2)
12 Autogenous 31 (13) 46.1 (16.3) 65 (10.2) 50.2 (14.5)
Menezes et al. [44] 2018 21 14 < 5 50% Biogran®;
50% autogenous 		6 NR NR Intermediate Apical NR NR
33.2 (13.3) 45.8 (13.8)
13 Autogenous 35 (13.9) 42 (16.6)
Pereira et al. [45] 2018 10 12 < 5 Biogran® 6 NR NR 52.1 NR NR
7 9 50% Biogran®; 50% autogenous 57.4
10 12 Autogenous bone 57.2

aP < 0.05 (Independent t-test); bP = 0.003 (Paired t-test); cP = 0.0001 (Kruskal-Wallis test); dP = 0.008 (Mann-Whitney test); eP < 0.0001 (Mann-Whitney test); fP < 0.0001 (Mann-Whitney test); gP < 0.0001 (Mann-Whitney test); hP = 0.0032 (Paired t-test); iP = 0.0001 (Paired t-test); jP < 0.0001 (Paired t-test).

BAF = bone area fraction; NFB = newly formed bone; NMT = non-mineralized tissue; PRP = platelet rich plasma; RBH = residual bone height; RCT = randomized controlled trial; SD = standard deviation; TBV = total bone volume.